Ocuphire Pharma, Inc. OCUP
We take great care to ensure that the data presented and summarized in this overview for Ocuphire Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OCUP
View all-
Bios Capital Management, LP Fort Worth, TX2.48MShares$2.43 Million3.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA992KShares$972,3560.0% of portfolio
-
Geode Capital Management, LLC Boston, MA314KShares$307,7040.0% of portfolio
-
Voss Capital, LLC Houston, TX191KShares$187,1380.02% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il176KShares$172,2570.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny146KShares$142,5980.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX117KShares$114,1700.0% of portfolio
-
Black Rock Inc. New York, NY107KShares$104,7960.0% of portfolio
-
State Street Corp Boston, MA70.5KShares$69,0630.0% of portfolio
-
Kestra Private Wealth Services, LLC48.3KShares$47,3740.0% of portfolio
Latest Institutional Activity in OCUP
Top Purchases
Top Sells
About OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Insider Transactions at OCUP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 13
2025
|
Ashwath Jayagopal Chief Scientific & Dev. Ofc. |
SELL
Payment of exercise price or tax liability
|
Direct |
5,193
-6.62%
|
$5,193
$1.15 P/Share
|
|
Feb 13
2025
|
Nirav S. Jhaveri Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,207
-5.47%
|
$8,207
$1.15 P/Share
|
|
Feb 04
2025
|
Bernhard Hoffmann SVP of Corp. Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,751
-4.15%
|
$6,751
$1.14 P/Share
|
|
Feb 04
2025
|
Rabourn Amy Zaremba SVP of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
8,190
-9.91%
|
$8,190
$1.14 P/Share
|
|
Jan 02
2025
|
Jean Bennett |
BUY
Grant, award, or other acquisition
|
Direct |
34,021
+20.25%
|
-
|
|
Jan 02
2025
|
James S J Manuso |
BUY
Grant, award, or other acquisition
|
Direct |
50,222
+21.6%
|
-
|
|
Dec 26
2024
|
George Magrath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+14.3%
|
$0
$0.98 P/Share
|
|
Dec 23
2024
|
George Magrath Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,200
+1.23%
|
-
|
|
Nov 21
2024
|
Benjamin R Yerxa President |
BUY
Open market or private purchase
|
Direct |
10,000
+2.83%
|
$0
$0.98 P/Share
|
|
Nov 18
2024
|
George Magrath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,706
+1.93%
|
$9,706
$1.02 P/Share
|
|
Nov 15
2024
|
George Magrath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
90,294
+15.74%
|
$90,294
$1.01 P/Share
|
|
Nov 07
2024
|
Benjamin R Yerxa President |
BUY
Grant, award, or other acquisition
|
Direct |
332,800
+50.0%
|
-
|
|
Nov 01
2024
|
George Magrath Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,050
-8.62%
|
$37,050
$1.18 P/Share
|
|
Oct 22
2024
|
Jean Bennett |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jun 11
2024
|
Jay Pepose |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+18.57%
|
-
|
|
Jun 11
2024
|
Richard J Rodgers |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+14.68%
|
-
|
|
Jun 11
2024
|
Susan Benton |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+22.71%
|
-
|
|
Jun 11
2024
|
Cam Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+34.81%
|
-
|
|
Jun 11
2024
|
James S J Manuso |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+23.76%
|
-
|
|
Jun 11
2024
|
Sean Ainsworth |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+31.77%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 802K shares |
|---|---|
| Open market or private purchase | 256K shares |
| Payment of exercise price or tax liability | 65.4K shares |
|---|